Loading
A phase 2 trial of JNJ-79635322, Tocilizumab in multiple myeloma, run by Janssen Research & Development, LLC, now recruiting.
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT07589634 by Janssen Research & Development, LLC, with 230 participants planned, started 2026-06-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: Ramantamig, Tocilizumab, Placebo. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares JNJ-79635322, Relapsed or refractory multiple myeloma, Johnson & Johnson, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Johnson & Johnson, T-cell engagers (bispecific), Monoclonal antibodies.
Shares Tocilizumab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Johnson & Johnson, T-cell engagers (bispecific), Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/